Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: A hyperinsulinemic-euglycemic clamp study

Sleep

Volumn 37, Issue 4, 2014, Pages 795-801

  Donjacour, Claire E H M ^a   Aziz, N Ahmad ^a   Overeem, Sebastiaan ^b,c   Kalsbeek, Andries ^d,e   Pijl, Hanno ^a   Lammers, Gert Jan ^a,f  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

^d NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

Diabetes; Hypocretin; Insulin; Orexin; Weight loss

Indexed keywords

GLUCOSE; GLYCEROL; OXYBATE SODIUM; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LIPID METABOLISM; LIPOLYSIS; MALE; NARCOLEPSY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; WEIGHT CHANGE; BODY COMPOSITION; CASE CONTROL STUDY; DEFICIENCY; DRUG EFFECTS; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; METABOLISM;

ADULT; BODY COMPOSITION; BODY WEIGHT; CASE-CONTROL STUDIES; FEMALE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN RESISTANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPID METABOLISM; LIPOLYSIS; MALE; NARCOLEPSY; NEUROPEPTIDES; SODIUM OXYBATE;

EID: 84897423039     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.3592     Document Type: Article

References (37)

1. Overeem S, Mignot E, VAN Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001; 18: 78-105.
2. Spiegel K, Knutson K, Leproult R, Tasali E, Cauter van E. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J Appl Physiol 2005; 99: 2008-19.
3. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-74.
4. Peyron C, Faraco J, Rogers W et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-7.
5. Willie JT, Chemelli RM, Sinton CM, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001; 24: 429-58.
6. Taylor MM, Samson WK. The other side of the orexins: endocrine and metabolic actions. Am J Physiol Endocrinol Metab 2003; 284: E13-7.
7. Girault EM, Yi CX, Fliers E, Kalsbeek A. Orexins, feeding, and energy balance. Prog Brain Res 2012; 198: 47-64.
8. Tsuneki H, Murata S, Anzawa Y, et al. Age-related insulin resistance in hypothalamus and peripheral tissues of orexin knockout mice. Diabetologia 2008; 51: 657-67.
9. Yi CX, Serlie MJ, Ackermans MT, et al. A major role for perifornical orexin neurons in the control of glucose metabolism in rats. Diabetes 2009; 58: 1998-2005.
10. Yi CX, Sun N, Ackermans MT, et al. Pituitary adenylate cyclase-activating polypeptide stimulates glucose production via the hepatic sympathetic innervation in rats. Diabetes 2010; 59: 1591-600.
11. Shiuchi T, Haque MS, Okamoto S, et al. Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell Metab 2009; 10: 466-80.
12. Honda Y, Doi Y, Ninomiya R, Ninomiya C. Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 1986; 9: 254-9.
13. Roberts HJ. The syndrome of narcolepsy and diabetogenic ("functional") hyperinsulinism. Observations on 190 patients, with emphasis upon its relationship to obesity, diabetes mellitus and cerebral dysrhythmias. J Fla Med Assoc 1963; 50: 355-66.
14. Roberts HJ. The syndrome of narcolepsy and diabetogenic ("functional") hyperinsulinism, with special reference to obesity, diabetes, idiopathic edema, cerebral dysrhythmias and multiple sclerosis (200 patients). J Am Geriatr Soc 1964; 12: 926-76.
15. Poli F, Plazzi G, Di DG, et al. Body mass index-independent metabolic alterations in narcolepsy with cataplexy. Sleep 2009; 32: 1491-7.
16. Engel A, Helfrich J, Manderscheid N, et al. Investigation of insulin resistance in narcoleptic patients: dependent or independent of body mass index? Neuropsychiatr Dis Treat 2011; 7: 351-6.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
18. Beitinger PA, Fulda S, Dalal MA, et al. Glucose tolerance in patients with narcolepsy. Sleep 2012; 35: 231-6.
19. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010; 33: 562-8.
20. Kahn SE. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 4047-58.
21. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-23.
22. The Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005; 1: 391-7.
23. Carter LP, Koek W, France CP. Behavioral analyses of GHB: receptor mechanisms. Pharmacol Ther 2009; 121: 100-14.
24. Pijl H. Reduced dopaminergic tone in hypothalamic neural circuits: expression of a "thrifty" genotype underlying the metabolic syndrome? Eur J Pharmacol 2003; 480: 125-31.
25. Husain AM, Ristanovic RK, Bogan RK. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med 2009; 10: 661-3.
26. American Academy of Sleep Medicine. American Sleep Association. International classification of sleep disorders. diagnostic and coding manual. 2nd ed. Westchester, IL: American Academy of Sleep Medicine, 2005.
27. Andersson BL, Bjorntorp P, Seidell JC. Measuring obesity-classification and description of anthropometric data report on a WHO consultation on epidemiology of obesity.1988;125: 1-22.
28. Liu D, Moberg E, Kollind M, Lins PE, Adamson U, Macdonald IA. Arterial, arterialized venous, venous and capillary blood glucose measurements in normal man during hyperinsulinaemic euglycaemia and hypoglycaemia. Diabetologia 1992; 35: 287-90.
29. Jazet IM, Pijl H, Frolich M, Romijn JA, Meinders AE. Two days of a very low calorie diet reduces endogenous glucose production in obese type 2 diabetic patients despite the withdrawal of blood glucose-lowering therapies including insulin. Metabolism 2005; 54: 705-12.
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
31. Steele ER. Infuences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 1959; 82: 420-30.
32. Kok SW, Overeem S, Visscher TL, et al. Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res 2003; 11: 1147-54.
33. Tsuneki H, Wada T, Sasaoka T. Role of orexin in the central regulation of glucose and energy homeostasis. Endocr J 2012; 59: 365-74.
34. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-70.
35. Khoza S, Barner JC, Bohman TM, Rascati K, Lawson K, Wilson JP. Use of antidepressant agents and the risk of type 2 diabetes. Eur J Clin Pharmacol 2012; 68: 1295-302.
36. Venner A, Karnani MM, Gonzalez JA, Jensen LT, Fugger L, Burdakov D. Orexin neurons as conditional glucosensors: paradoxical regulation of sugar sensing by intracellular fuels. J Physiol 2011; 589: 5701-8.
37. Kalsbeek A, Yi CX, La Fleur SE, Fliers E. The hypothalamic clock and its control of glucose homeostasis. Trends Endocrinol Metab 2010; 21: 402-10.